Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways

Hepatology

Volumn 55, Issue 6, 2012, Pages 1820-1829

  Chen, Qiang ^a,b,c   Li, Wenjiao ^b   Wan, Yunyan ^a   Xia, Xiaochun ^b   Wu, Qiao ^b   Chen, Yanling ^d   Lai, Zhide ^d   Yu, Chundong ^b   Li, Wengang ^a  

^a The Affiliated Chenggong Hospital of Xiamen University   (China)

^b XIAMEN UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^d FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE 1; GLUTATHIONE PEROXIDASE; GLUTATHIONE SYNTHASE; PROTEIN BCL 2; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STEROID RECEPTOR COACTIVATOR 3; TRANSCRIPTION FACTOR NRF2;

ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER RESISTANCE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME REPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; UPREGULATION;

ATP-BINDING CASSETTE TRANSPORTERS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NF-E2-RELATED FACTOR 2; NUCLEAR RECEPTOR COACTIVATOR 3; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 84861573429     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25549     Document Type: Article

References (20)

1. Tyson GL, El-Serag HB. Risk factors of cholangiocarcinoma. HEPATOLOGY 2011; 54: 173-184.
2. Singal AK, Vauthey JN, Grady JJ, Stroehlein JR. Intra-hepatic cholangiocarcinoma-frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center. J Cancer Res Clin Oncol 2011; 137: 1071-1078.
3. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366: 1303-1314.
4. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. HEPATOLOGY 2005; 41: 5-15.
5. Xu J, Wu RC, O'Malley BW. Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 2009; 9: 615-630.
6. Yan J, Tsai SY, Tsai MJ. SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta Pharmacol Sin 2006; 27: 387-394.
7. Okumura E, Fukuhara T, Yoshida H, Hanada Si S, Kozutsumi R, Mori M, et al. Akt inhibits Myt1 in the signalling pathway that leads to meiotic G2/M-phase transition. Nat Cell Biol 2002; 4: 111-116.
8. Lee SR, Park JH, Park EK, Chung CH, Kang SS, Bang OS. Akt-induced promotion of cell-cycle progression at G2/M phase involves upregulation of NF-Y binding activity in PC12 cells. J Cell Physiol 2005; 205: 270-277.
9. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 2000; 275: 10761-10766.
10. Chen Q, Chen T, Xu Y, Zhu J, Jiang Y, Zhao Y, et al. Steroid receptor coactivator 3 is required for clearing bacteria and repressing inflammatory response in Escherichia coli-induced septic peritonitis. J Immunol 2010; 185: 5444-5452.
11. Hildeman DA, Mitchell T, Aronow B, Wojciechowski S, Kappler J, Marrack P. Control of Bcl-2 expression by reactive oxygen species. Proc Natl Acad Sci U S A 2003; 100: 15035-15040.
12. Lu SC. Regulation of glutathione synthesis. Mol Aspects Med 2009; 30: 42-59.
13. Banning A, Deubel S, Kluth D, Zhou Z, Brigelius-Flohe R. The GI-GPx gene is a target for Nrf2. Mol Cell Biol 2005; 25: 4914-4923.
14. Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene 2003; 22: 7496-7511.
15. Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, Rue M, et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004; 6: 263-274.
16. Yan J, Yu CT, Ozen M, Ittmann M, Tsai SY, Tsai MJ. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res 2006; 66: 11039-11046.
17. Xu Y, Chen Q, Li W, Su X, Chen T, Liu Y, et al. Overexpression of transcriptional coactivator AIB1 promotes hepatocellular carcinoma progression by enhancing cell proliferation and invasiveness. Oncogene 2010; 29: 3386-3397.
18. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003; 2: 339-345.
19. Harnois DM, Que FG, Celli A, LaRusso NF, Gores GJ. Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. HEPATOLOGY 1997; 26: 884-890.
20. Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, et al. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008; 14: 458-470.